Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2021-06-30 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please ....
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report for the year ended March 31, 2021' and is addressed to stock exchanges. It references compliance with SEBI regulations and lists deviations and observations related to secretarial and regulatory compliance for the financial year ended March 31, 2021. The content is a compliance certification report by a company secretary firm, examining adherence to various SEBI regulations and listing obligations. It does not contain financial statements or management discussion of financial results, nor is it an announcement of voting results or board changes. It is a regulatory compliance report focused on secretarial matters, not an annual report or audit report. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a compliance report that does not fit into other specific categories like Annual Report or Audit Report.
2021-06-30 English
This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) ....
Regulatory Filings Classification · 95% confidence The document is a formal notice from Bliss GVS Pharma Ltd. addressed to stock exchanges about the closure of the trading window starting July 1, 2021, until 48 hours after the announcement of the unaudited financial results for the quarter ended June 30, 2021. It references regulatory compliance with insider trading regulations and internal codes but does not contain any financial data or results itself. The document is an announcement related to trading restrictions ahead of financial results disclosure, not the financial results or report itself. The document length is short (2481 characters) and serves as a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory notices that do not fit other specific categories.
2021-06-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from Bliss GVS Pharma Ltd. addressed to stock exchanges regarding the closure of the trading window effective July 1, 2021, until 48 hours after the announcement of the unaudited financial results for the quarter ended June 30, 2021. It references regulatory compliance with insider trading regulations and internal codes of conduct. The document does not contain any financial data or results itself, nor does it include a report or detailed financial statements. It is an announcement related to trading restrictions ahead of a financial results announcement. The document length is short (2481 characters), and it serves as an intimation or notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-30 English
Related Party Transactions
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 122 characters, indicating it is extremely short and does not contain any report content. It does not provide any financial statements, management discussion, or regulatory information. Given the lack of content, this document cannot be classified as a report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2021-06-10 English
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed disclosure of Related ....
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 122 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and should be classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without substantive content.
2021-06-10 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polus Global Fund
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, specifically Regulation 29(2). It details the sale of equity shares by Polus Global Fund in Bliss GVS Pharma Limited, including shareholding percentages before and after the transaction, mode of acquisition (open market), and dates. The document is a formal notification of a change in significant shareholding, not a financial report, earnings release, or management discussion. It fits the definition of a Major Shareholding Notification (MRQ).
2021-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.